Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Lung Cancer Therapy Using Doxorubicin And Curcumin Combination: Targeted Prodrug Based, PH Sensitive Nanomedicine.

Y. Hong, S. Che, Beina Hui, Yunyi Yang, X. Wang, Xiaozhi Zhang, Yongqian Qiang, Hailin Ma
Published 2019 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Lung cancer is the leading cause of cancer death worldwide. To overcome the toxic side effects and multidrug resistance (MDR) during doxorubicin (DOX) chemotherapy, a urokinase plasminogen activator receptor (uPAR) targeting U11 peptide decorated, pH-sensitive, dual drugs co-encapsulated nanoparticles (NPs) system is employed in this study. A U11 peptide conjugated, pH-sensitive DOX prodrug (U11-DOX) was synthesized and used as materials to produce NPs. A curcumin (CUR) and U11-DOX co-encapsulated NPs system (U11-DOX/CUR NPs) was constructed to treat lung cancer. After the characterization of biophysical properties of this NPs system, synergistic chemotherapeutic efficacy was evaluated in both cultured cancer cells and tumor-bearing animal model. U11-DOX/CUR NPs had a uniformly spherical shape with a core-shell structure. The mean particle size and zeta potential of the U11-DOX/CUR NPs was 121.3 nm and -33.5 mV, with a DOX and CUR EE of 81.7 and 90.5%, respectively. The DOX release from U11-DOX/CUR NPs was 83.5, 55.2, and 32.8% correspondence to the pH of 5.0, 6.0 and 7.4. Cellular uptake efficiency of U11-DOX/CUR NPs was significantly higher than non U11 peptide decorated DOX/CUR NPs. U11-DOX/CUR NPs displayed a pronounced synergy effects in vitro and an obvious tumor tissue accumulation efficiency in vivo. In vivo antitumor experiment showed that U11-DOX/CUR NPs could inhibit the tumor growth to a level of 85%.In vitro and in vivo studies demonstrated that U11-DOX/CUR NPs is a sustained released, pH responsive, synergistic antitumor system. This study suggests that the U11-DOX/CUR NPs have promising potential for combination treatment of lung cancer.
This paper references
10.1016/j.biomaterials.2015.07.027
Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy.
P. Zhang (2015)
10.1371/journal.pone.0131579
Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells
Lihong Mo (2015)
10.1007/978-3-319-24223-1_1
Lung Cancer Statistics.
L. Torre (2016)
10.1016/j.biopha.2016.12.042
Construction and comparison of different nanocarriers for co-delivery of cisplatin and curcumin: A synergistic combination nanotherapy for cervical cancer.
Changming Li (2017)
10.2147/DDDT.S166749
Atrial natriuretic peptide modified oleate adenosine prodrug lipid nanocarriers for the treatment of myocardial infarction: in vitro and in vivo evaluation
J. Yu (2018)
10.1016/S0169-5002(97)00032-9
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
H. Pappot (1997)
10.2147/DDDT.S143047
Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer
R. Zhang (2017)
10.1016/j.phrs.2010.07.004
Influence of peroxisome proliferator-activated receptor-alpha (PPARα) activity on adverse effects associated with amiodarone exposure in mice.
Matthew C. Ernst (2010)
10.1021/acs.biomac.8b00213
Rational Design of Multifunctional Polymeric Nanoparticles Based on Poly(l-histidine) and d-α-Vitamin E Succinate for Reversing Tumor Multidrug Resistance.
Z. Li (2018)
10.1016/j.addr.2009.11.021
Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs.
S. Gunaseelan (2010)
10.1016/S0142-9612(00)00143-5
Receptor-mediated cell modulator delivery to hepatocyte using nanoparticles coated with carbohydrate-carrying polymers.
C. Cho (2001)
10.2147/IJN.S115136
Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer
B. Liu (2017)
10.1016/j.actbio.2018.02.008
pH-sensitive doxorubicin-conjugated prodrug micelles with charge-conversion for cancer therapy.
B. Ma (2018)
10.1016/j.nucmedbio.2016.05.010
PEGylated nanoliposomes encapsulating angiogenic peptides improve perfusion defects: Radionuclide imaging-based study.
Hyosook Hwang (2016)
10.1021/bc8001908
Targeting the urokinase plasminogen activator receptor with synthetic self-assembly nanoparticles.
M. Wang (2009)
10.1038/srep38541
Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells
A. Srivastava (2016)
10.1002/adhm.201400108
Synergistic antitumor effects of doxorubicin-loaded carboxymethyl cellulose nanoparticle in combination with endostar for effective treatment of non-small-cell lung cancer.
Mingqiang Li (2014)
10.1039/c7nr08176f
NO prodrug-conjugated, self-assembled, pH-responsive and galactose receptor targeted nanoparticles for co-delivery of nitric oxide and doxorubicin.
J. Zhang (2018)
10.1111/j.1600-0463.2012.02955.x
The liberated domain I of urokinase plasminogen activator receptor – a new tumour marker in small cell lung cancer
C. E. Almasi (2013)
10.1016/j.nano.2012.11.008
Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft.
Kevin S. Chu (2013)
10.1007/s13277-016-5364-8
Natural products against cancer angiogenesis
El Bairi Khalid (2016)
10.2147/IJN.S63155
Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans
Q. Zia (2015)
Induction of apoptosis and reversal of permeability glycoprotein-mediated multidrug resistance of MCF-7/ADM by ginsenoside Rh2.
H. Zhang (2015)
10.1021/acs.bioconjchem.5b00005
Peptide-nanoparticle ligation mediated by cutinase fusion for the development of cancer cell-targeted nanoconjugates.
E. Galbiati (2015)
10.3402/jev.v4.25530
Simplified protocol for flow cytometry analysis of fluorescently labeled exosomes and microvesicles using dedicated flow cytometer
Vendula Pospíchalová (2015)
10.2147/IJN.S57939
Tissue distribution and excretion kinetics of orally administered silica nanoparticles in rats
J. Lee (2014)
10.2147/IJN.S20165
Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA
Lekha Nair K (2011)
10.1016/j.carbpol.2015.10.050
pH-sensitive polymeric micelles formed by doxorubicin conjugated prodrugs for co-delivery of doxorubicin and paclitaxel.
Yakun Ma (2016)
10.1155/2017/9090325
Targeted Therapeutic Nanoparticles: An Immense Promise to Fight against Cancer
S. Jahan (2017)
10.1016/j.biopha.2017.08.090
Combination lung cancer chemotherapy: Design of a pH-sensitive transferrin-PEG-Hz-lipid conjugate for the co-delivery of docetaxel and baicalin.
Shuang Li (2017)
10.1007/s11523-014-0321-1
Curcumin and lung cancer—a review
H. Mehta (2014)
10.1016/j.jconrel.2013.09.013
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles.
M. J. Ernsting (2013)
10.1097/CAD.0000000000000527
Calcein-acetoxymethy ester enhances the antitumor effects of doxorubicin in nonsmall cell lung cancer by regulating the TopBP1/p53RR pathway
Yinxiang Lv (2017)
10.2147/IJN.S149887
Aptamer–drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity
Xiao-qian Dou (2018)
10.2147/IJN.S32053
Effects of pH-sensitive chain length on release of doxorubicin from mPEG-b-PH-b-PLLA nanoparticles
R. Liu (2012)
10.1016/j.actbio.2015.05.017
A drug carrier targeting murine uPAR for photodynamic therapy and tumor imaging.
X. Zhou (2015)
10.3109/10717544.2015.1126769
EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer
X. Zhang (2016)
10.7150/thno.8527
A Novel Tumor Targeting Drug Carrier for Optical Imaging and Therapy
R. Li (2014)
10.2147/IJN.S161163
Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy
Jicai Zhang (2018)
10.2147/IJN.S49459
Dextran-b-poly(L-histidine) copolymer nanoparticles for ph-responsive drug delivery to tumor cells
Jong-ho Hwang (2013)
10.1016/j.biopha.2018.05.095
Endothelial growth factor receptor-targeted and reactive oxygen species-responsive lung cancer therapy by docetaxel and resveratrol encapsulated lipid-polymer hybrid nanoparticles.
Zizheng Song (2018)
10.1038/srep21225
Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer
Y. Zhang (2016)
10.2147/IJN.S93237
Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy
Narsireddy Amreddy (2015)
10.2147/IJN.S51949
High-efficiency liposomal encapsulation of a tyrosine kinase inhibitor leads to improved in vivo toxicity and tumor response profile
R. Mukthavaram (2013)
10.22037/IJPR.2018.2239
Co -delivery of Sulforaphane and Curcumin with PEGylated Iron Oxide-Gold Core Shell Nanoparticles for Delivery to Breast Cancer Cell Line
H. Danafar (2018)
10.2147/IJN.S149306
Surface-enhanced Raman scattering investigation of targeted delivery and controlled release of gemcitabine
T. Santiago (2017)
10.3892/or.2017.5345
Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment.
Tongxing Cui (2017)
10.3390/ijms17091440
Surface Modified Multifunctional and Stimuli Responsive Nanoparticles for Drug Targeting: Current Status and Uses
P. Siafaka (2016)
10.1016/j.jconrel.2010.10.030
Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy.
M. O. Abdalla (2011)
10.1016/j.biotechadv.2013.10.002
Nanoparticles containing insoluble drug for cancer therapy.
S. Guo (2014)
10.1016/j.biopha.2016.12.138
Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer.
Jieke Yan (2017)
10.1080/10717544.2017.1381201
Self-delivering prodrug-nanoassemblies fabricated by disulfide bond bridged oleate prodrug of docetaxel for breast cancer therapy
Shenwu Zhang (2017)
10.2147/IJN.S31757
pH and temperature dual-sensitive liposome gel based on novel cleavable mPEG-Hz-CHEMS polymeric vaginal delivery system
D. Chen (2012)
10.1016/j.jconrel.2016.07.051
Role of nanoparticle size, shape and surface chemistry in oral drug delivery.
Amrita Banerjee (2016)
10.1016/j.jconrel.2008.05.003
Recent progress in tumor pH targeting nanotechnology.
E. Lee (2008)
10.1016/j.ccm.2011.09.001
Lung cancer: epidemiology, etiology, and prevention.
C. D. Dela Cruz (2011)
10.1142/S0192415X16500609
Modified Panax ginseng Extract Inhibits uPAR-Mediated α[Formula: see text]β1-Integrin Signaling by Modulating Caveolin-1 to Induce Early Apoptosis in Lung Cancer Cells.
I. Hwang (2016)
10.2147/DDDT.S151422
Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo
S. Tan (2017)
10.1016/j.biopha.2018.01.062
Transferrin and tocopheryl-polyethylene glycol-succinate dual ligands decorated, cisplatin loaded nano-sized system for the treatment of lung cancer.
Guo-bin Xu (2018)
10.2147/IJN.S70087
Cytotoxicity and antibacterial activity of gold-supported cerium oxide nanoparticles
K. Suresh Babu (2014)
10.1021/mp500177c
uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.
M. Persson (2014)
10.2147/IJN.S32188
A physical model for the size-dependent cellular uptake of nanoparticles modified with cationic surfactants
A. Xu (2012)
Growth inhibition of MDA-MB-231 cell line by peptides designed based on uPA.
P. Tarighi (2015)



This paper is referenced by
10.2147/DDDT.S241291
Combination Therapy of Lung Cancer Using Layer-by-Layer Cisplatin Prodrug and Curcumin Co-Encapsulated Nanomedicine
Y. Hong (2020)
10.3390/ph13010002
Dextran-Curcumin Nanoparticles as a Methotrexate Delivery Vehicle: A Step Forward in Breast Cancer Combination Therapy
M. Curcio (2019)
10.1002/adhm.202001128
Carrier-Free Nanoassembly of Curcumin-Erlotinib Conjugate for Cancer Targeted Therapy.
Chen Cheng (2020)
10.3390/ijms21165832
Controlled Drug Release and Cytotoxicity Studies of Beta-Lapachone and Doxorubicin Loaded into Cyclodextrins Attached to a Polyethyleneimine Matrix
A. Kowalczyk (2020)
10.2147/DDDT.S270303
Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib
Na Yin (2020)
10.1002/jcp.29819
Versatile role of curcumin and its derivatives in lung cancer therapy
M. Ashrafizadeh (2020)
10.1016/j.biopha.2019.109225
Synergistic combination therapy of lung cancer: Cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-Demethylnobiletin.
Shenghu Guo (2019)
10.2147/IJN.S213942
Analysis of toxicity and anticancer activity of micelles of sodium alginate-curcumin
Alicja Karabasz (2019)
10.3390/jpm10040263
Expression of ATP/GTP Binding Protein 1 Has Prognostic Value for the Clinical Outcomes in Non-Small Cell Lung Carcinoma
Hee Jeong Kwak (2020)
10.1049/iet-nbt.2020.0073
Surface-functionalised hybrid nanoparticles for targeted treatment of cancer.
Hasnat Tariq (2020)
10.2147/DDDT.S256636
Synergistic Effect of Tangeretin and Atorvastatin for Colon Cancer Combination Therapy: Targeted Delivery of These Dual Drugs Using RGD Peptide Decorated Nanocarriers
He Bao (2020)
10.1016/j.biopha.2019.109006
Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo.
G. Zheng (2019)
10.1039/c9ra08202f
CD44-targeted hyaluronic acid–curcumin reverses chemotherapeutics resistance by inhibiting P-gp and anti-apoptotic pathways
L. Diao (2019)
10.3390/nano10081556
Efficacy of Polymer-Based Nanocarriers for Co-Delivery of Curcumin and Selected Anticancer Drugs
S. Alven (2020)
10.1007/s10847-020-00994-z
Impact of pH and cell medium on the interaction of doxorubicin with lipoic acid cyclodextrin conjugate as the drug carrier
Olga Swiech (2020)
10.1016/j.biopha.2020.110369
Developing neobavaisoflavone nanoemulsion suppresses lung cancer progression by regulating tumor microenvironment.
H. Ye (2020)
10.1080/10717544.2020.1837294
Chemo-immune synergetic therapy of esophageal carcinoma: trastuzumab modified, cisplatin and fluorouracil co-delivered lipid–polymer hybrid nanoparticles
Qingxia Fu (2020)
10.2147/DDDT.S260253
Synergistic Combination Chemotherapy of Lung Cancer: Cisplatin and Doxorubicin Conjugated Prodrug Loaded, Glutathione and pH Sensitive Nanocarriers
Yonglong Jin (2020)
10.3390/ijms20174293
Quercetin Enhances the Anti-Tumor Effects of BET Inhibitors by Suppressing hnRNPA1
T. N. Pham (2019)
Design of Functional Polymeric Nanoparticles for Biomedical Applications
Heba Asem (2020)
10.1088/1755-1315/439/1/012062
Cytotoxic effects of chemopreventive agents curcumin, naringin and epigallocathecin-3-gallate in C2C12 myoblast cells
E. P. Septisetyani (2020)
10.1016/j.biopha.2020.110009
Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
Sara S. Bashraheel (2020)
Semantic Scholar Logo Some data provided by SemanticScholar